Day: October 17, 2017

Chairman and Distinguished Professor of Ophthalmology at the University of California.

Proof genetic contribution in the pathogenesis of POAG is certainly well established. Since POAG will run in family members, it is advisable to identify the genetic basis of the condition in order to develop effective therapies for early intervention. A better understanding of the partnership among the stage of disease, the price of switch, ancestry, and other essential risk factors getting tracked in the ongoing African Descent and Glaucoma Study will allow us to assess the partnership between genetics, visual reduction and structural damage in this high-risk group, added Linda Zangwil, PhD, a professor of ophthalmology at UC San Diego and study co-investigator. The analysis will obtain detailed phenotypes – a composite of most observed characteristics or characteristics of a person – of more than 2,000 topics, set up a repository and implement a data-coordinating center at UC San Diego, aswell conduct comprehensive genetic studies. Read More

Chester Ridgway.

Paul W. Ladenson, M.D all reviews here ., Jens D. Kristensen, M.D., Ph.D., E. Chester Ridgway, M.D., Anders G. Olsson, M.D., Ph.D., Bo Carlsson, M.Sc., Irwin Klein, M.D., John D. Baxter, M.D., and Bo Angelin, M.D., Ph.D.: Usage of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia The association between elevated degrees of circulating low-density lipoprotein cholesterol and an elevated risk of atherosclerotic coronary disease is well established,1 as will be the reductions in both degrees of serum cholesterol and the risk of coronary disease that occur by using inhibitors of hepatic 3-hydroxy-3-methyl-glutaryl coenzyme A reductase.1 However, the efficacy of statins is limited if stringent goals for serum LDL cholesterol amounts aren’t achieved2 in patients receiving statins alone3 or if side effects develop that require a dose reduction or discontinuation of the agent.4 Furthermore, statins are less effective in lowering levels of other lipoproteins, such as triglycerides5 and Lp lipoprotein,6 that are associated with the risk of atherosclerotic vascular disease.9 Consequently, additional agents that target the metabolism of lipoproteins to improve outcomes in patients with cardiovascular disease will be beneficial. Read More